Fagerström K O, Tejding R, Westin A, Lunell E
Pharmacia & Upjohn Consumer Healthcare, Helsingborg, Sweden.
Tob Control. 1997 Winter;6(4):311-6. doi: 10.1136/tc.6.4.311.
To assess the effect of the various nicotine replacement therapies (NRT) on smoking reduction.
During an initial sampling week, the subjects familiarised themselves with nicotine gum, patch, nasal spray, vaporiser (vapour inhaler) and sublingual tablet. A crossover design was used during the next four study weeks; during two of these weeks the subjects could select one nicotine replacement product of their choice to use, whereas during the other two they were randomly assigned a product to use.
143 men and women smoking an average of 22.6 (SD 7.0) cigarettes per day and exhibiting a Fagerström Tolerance Questionnaire (FTQ) score of 7.0 (SD 1.9).
Subjects were asked to use as much NRT as they wished, yet to smoke enough to feel comfortable.
Self-reported cigarette consumption, exhaled carbon monoxide (CO), withdrawal symptom score, cotinine plasma levels and motivation to quit were monitored over a period of five weeks.
Self-reported smoking declined steadily over the five weeks, from 22.6 (SD 7.0) to 10.4 (SD 1.0) (P<0.001) cigarettes daily (54% decrease), with the biggest drop (37%) during the first product-sampling week. Smoking reduction was greater on average during the weeks when the subjects could choose their nicotine product than when products were assigned. CO readings decreased from 22.7 (SD 8.5) to 14.8 (SD 8.4) ppm (P<0.001) confirming a reduction in smoking (35% decrease), although cotinine levels remained steady, suggesting that subjects were titrating nicotine to their original levels. Withdrawal scores decreased over time (32% decrease, P<0.001), showing that there was no discomfort associated with the smoking reduction, and motivation to quit was enhanced by the treatment in most subjects (93%).
NRT for aiding smoking reduction appeared to be safe, was associated with a clinically significant reduction in smoke exposure over a five-week follow up, and increased motivation to stop smoking. A smoking reduction procedure may help the very recalcitrant smoker gain confidence and increase the control over his/her smoking behaviour. More controlled research is needed to follow up these promising results.
评估各种尼古丁替代疗法(NRT)对减少吸烟的效果。
在初始采样周期间,受试者熟悉尼古丁口香糖、贴片、鼻喷雾剂、蒸发器(蒸汽吸入器)和舌下片。在接下来的四个研究周采用交叉设计;在其中两周,受试者可以选择一种他们喜欢的尼古丁替代产品使用,而在另外两周,他们被随机分配一种产品使用。
143名男性和女性,平均每天吸烟22.6支(标准差7.0),法格斯特龙耐受问卷(FTQ)评分为7.0(标准差1.9)。
要求受试者根据自身意愿使用尽可能多的NRT,但也要吸足够的烟以保持舒适。
在五周的时间内监测自我报告的香烟消费量、呼出一氧化碳(CO)、戒断症状评分、可替宁血浆水平和戒烟动机。
自我报告的吸烟量在五周内稳步下降,从每天22.6支(标准差7.0)降至10.4支(标准差1.0)(P<0.001)(减少54%),在第一个产品采样周下降幅度最大(37%)。受试者可以选择尼古丁产品的几周内平均吸烟减少量大于产品被分配使用的几周。CO读数从22.7ppm(标准差8.5)降至14.8ppm(标准差8.4)(P<0.001),证实吸烟减少(减少35%),尽管可替宁水平保持稳定,表明受试者将尼古丁剂量调整至原来水平。戒断评分随时间下降(下降32%,P<0.001),表明减少吸烟没有带来不适,并且在大多数受试者中(93%)治疗增强了戒烟动机。
用于帮助减少吸烟的NRT似乎是安全的,在为期五周的随访中与临床上显著减少烟雾暴露相关,并且增加了戒烟动机。减少吸烟程序可能有助于非常顽固的吸烟者获得信心并增强对其吸烟行为的控制。需要更多对照研究来跟进这些有前景的结果。